Acute Tubular Necrosis

• Ischemic injury and cellular hypoxia: In ischemic ATN (the predominant form), renal hypoperfusion—from sepsis, cardiogenic shock, major surgery, or volume depletion—reduces oxygen delivery to the highly metabolically active proximal tubular epithelium. The proximal tubule epithelium has extremely high metabolic demands due to active sodium reabsorption, making it exquisitely vulnerable to ischemia. When renal perfusion pressure falls below the autoregulatory threshold (~80 mmHg mean arterial pressure), oxygen delivery becomes flow-dependent. This triggers rapid depletion of ATP, which causes failure of Na+/K+-ATPase pumps, leading to intracellular sodium and calcium accumulation, cell swelling, and activation of proteases and phospholipases. Mitochondrial dysfunction and generation of reactive oxygen species (ROS) accelerate cellular injury. The lack of ATP also causes loss of microvilli, disruption of tight junctions (claudins and occludin), and shedding of viable tubular epithelial cells into the tubular lumen.

• Loss of epithelial barrier integrity and backleak: As tubular epithelial cells are damaged and sloughed, the tight junction complexes that normally maintain a selectively permeable barrier are disrupted. This allows increased paracellular leak of glomerular filtrate back into the peritubular capillaries and interstitium (so-called "backleak"), which significantly reduces net urine output despite continued glomerular filtration. The denuded tubular basement membrane becomes exposed, and frank breaks may occur. Dedifferentiation of surviving epithelial cells causes loss of specialized transport functions. This backleak of filtrate containing urinary electrolytes and solutes contributes to hyperkalemia, hyperphosphatemia, and uremia despite apparent glomerular filtration.

• Nephrotoxic injury mechanisms: In toxic ATN, nephrotoxins cause direct epithelial damage through multiple pathways. Aminoglycosides accumulate in proximal tubular cells via megalin-mediated endocytosis and bind to mitochondria, causing oxidative damage and ATP depletion similar to ischemia. Contrast-induced AKI involves both osmotic stress (contrast hyperosmolality causing cell dehydration and apoptosis), oxidative stress, and direct endothelial injury leading to vasoconstriction. Myoglobin and hemoglobin from rhabdomyolysis or massive hemolysis create toxic compounds (ferric myoglobin) in the acidic tubular environment and cause oxidative injury; additionally, myoglobin precipitation in acidic tubules physically obstructs flow. Cisplatin forms DNA adducts and triggers apoptosis. Heavy metals (mercury, arsenic) inhibit critical sulfhydryl-containing enzymes. Amphotericin B forms pores in cell membranes, causing direct osmotic lysis. NSAIDs reduce renal perfusion by inhibiting protective prostaglandins while also directly damaging tubular cells.

• Tubular obstruction and cast formation: Sloughed epithelial cells, cellular debris, and protein precipitates accumulate in the tubular lumen, forming "muddy brown casts" (composed of myoglobin, hemoglobin, or cellular debris). These casts physically obstruct the tubular lumen and increase intraluminal pressure, further reducing the effective filtration pressure gradient (Pnet = PGC - PBS - πGC). In rhabdomyolysis-associated ATN, myoglobin precipitation is exacerbated by acidic urine pH, making alkalinization therapeutically important.

• Inflammatory cascade and microvascular injury: Ischemic injury triggers toll-like receptor (TLR) signaling and inflammasome activation, leading to release of pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) and chemokines. These promote neutrophil infiltration and activate endothelial cells, causing further microvascular injury. Endothelial glycocalyx shedding impairs vasodilation and promotes leukostasis. In septic ATN, lipopolysaccharides and bacterial products intensify this inflammatory response. The resulting increase in vascular permeability and interstitial edema further compromises renal perfusion through elevated interstitial pressure.

• Impaired autoregulation and vasoconstriction: Normally, the kidney maintains constant glomerular filtration despite changes in systemic blood pressure through myogenic reflexes and tubuloglomerular feedback. ATN and associated inflammation impair these mechanisms. Additionally, loss of local vasodilatory signals (decreased renal perfusion → decreased macula densa signaling and decreased nitric oxide production) combined with increased vasoconstrictor tone from the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system causes persistent renal vasoconstriction, perpetuating ischemia even if systemic perfusion is restored.

• Apoptosis and delayed regeneration: Surviving epithelial cells may undergo apoptosis through caspase-dependent and caspase-independent pathways triggered by ischemia and oxidative stress. This extends the injury phase. Additionally, the surviving epithelial cells must dedifferentiate, migrate, and proliferate to restore the epithelial monolayer—a process taking 3-7 days. During this repair phase, tubular function remains impaired.

• Sepsis and septic shock: The most common single cause of ATN in ICU patients. Sepsis causes systemic vasodilation with relative renal vasoconstriction, myocardial depression, and direct endothelial injury from inflammatory mediators. Gram-negative sepsis is particularly associated with ATN due to endotoxin-mediated RAAS and sympathetic activation.
• Cardiogenic shock: Reduced cardiac output from acute myocardial infarction, acute decompensated heart failure, fulminant myocarditis, or massive pulmonary embolism reduces renal perfusion pressure below autoregulatory threshold. This is especially dangerous because the hypotension is often prolonged.
• Hypovolemic shock: Severe hemorrhage (trauma, GI bleeding), severe dehydration, or large third-spacing (pancreatitis, burns) reduces circulating volume and renal perfusion. Major surgery induces a combination of hypovolemia and direct ischemic injury from aortic clamping.
• Major surgery: Particularly cardiopulmonary bypass, vascular surgery, and surgery in elderly or diabetic patients. Bypass causes non-pulsatile flow, hemodilution, and systemic inflammation.
• Aortic cross-clamping: Direct renal ischemia during aortic surgery.
• Renal artery stenosis/thrombosis: Can cause profound renal ischemia, though usually affects one kidney unless bilateral disease.

• Aminoglycoside antibiotics (gentamicin, tobramycin, amikacin): Cause dose-dependent and time-dependent nephrotoxicity. Risk increases with prolonged use (>5-7 days), pre-existing renal disease, age >60, dehydration, and concurrent nephrotoxins. Though relatively uncommon in modern practice due to availability of alternatives, they remain a classic board association.
• Amphotericin B: Particularly the conventional formulation; causes ATN in up to 80% of patients. Risk increases with cumulative dose and pre-existing renal disease. Lipid formulations are less nephrotoxic.
• Contrast-induced AKI (CI-AKI): Occurs in 5-25% of high-risk patients receiving iodinated radiocontrast media. High-osmolality agents cause more injury than iso-osmolal agents. Risk increases dramatically with pre-existing renal disease (especially diabetes with GFR <30), dehydration, advanced age, heart failure, and concurrent nephrotoxins.
• Cisplatin and other chemotherapy: Cumulative dose-dependent toxicity; cisplatin-induced AKI occurs in 30-50% of treated patients. Other agents (ifosfamide, methotrexate) also cause ATN.
• NSAIDs: Cause ATN through hemodynamic mechanisms (inhibition of protective prostaglandins) combined with direct toxic effects. Risk increases with volume depletion, pre-existing renal disease, liver disease, heart failure, and concurrent ACE-I/ARB use (triple whammy syndrome).
• ACE inhibitors and ARBs: Primarily cause hemodynamic AKI through loss of efferent arteriolar vasoconstriction, but can cause ATN in volume-depleted patients. "Triple whammy" (NSAIDs + ACE-I/ARB + diuretics) significantly increases risk.
• Myoglobin (rhabdomyolysis-associated ATN): Massive muscle injury from crush injury, extreme exertion, statins, neuroleptic malignant syndrome, or malignant hyperthermia releases myoglobin, which precipitates in renal tubules and causes direct toxic injury. CK levels >5000 IU/L are associated with significant myoglobinuria risk.
• Hemoglobin (hemolysis-associated ATN): Intravascular hemolysis from transfusion reactions, hemolytic uremic syndrome, thrombotic thrombocytopenic purpura, or sickle cell crisis releases hemoglobin, which causes similar tubular injury as myoglobin.
• Light chains (multiple myeloma): Monoclonal free light chains precipitate in renal tubules, causing "myeloma kidney" (cast nephropathy), a form of ATN. Risk increases with high light chain burden and dehydration.
• Uric acid: Acute hyperuricemia from tumor lysis syndrome (especially in hematologic malignancies) causes ATN through tubular precipitation, particularly in acidic urine.
• Ethylene glycol and methanol: Metabolites cause direct tubular toxicity and systemic acidosis.
• Heavy metals: Mercury, arsenic, and lead cause proximal tubular necrosis.
• Herbal remedies: Chinese herbs (aristolochic acid) and others cause chronic kidney disease but may present acutely.

Risk factors increasing susceptibility to both ischemic and nephrotoxic ATN

• Chronic kidney disease: Reduced functional renal mass and impaired autoregulation increase susceptibility.
• Diabetes mellitus: Impaired renal autoregulation, microvascular disease, and oxidative stress increase vulnerability.
• Advanced age: Reduced functional nephron mass, impaired autoregulation, and baseline medications increase risk.
• Volume depletion: Activates RAAS and compromises renal perfusion.
• Liver disease: Impaired synthetic function, portal hypertension with splanchnic vasodilation, and hepatorenal physiology increase AKI risk.
• Congestive heart failure: Reduced cardiac output and neurohormonal activation compromise renal perfusion.
• Concomitant medications: Combination of NSAIDs, ACE-I/ARB, and diuretics ("triple whammy"); aminoglycosides with amphotericin B; metformin (lactic acidosis risk).

Cardinal features of ATN

• Oliguria or non-oliguria: ATN classically presents with oliguria (urine output <400-500 mL/day), though non-oliguric AKI (urine output >400 mL/day despite reduced GFR) is increasingly recognized and carries a better prognosis. The distinction reflects severity of tubular damage and residual function; oliguria indicates more severe epithelial damage or greater degree of backleak. Non-oliguric ATN may be subclinical initially, detected only by rising serum creatinine without noticeable change in urine output.

• Rapid rise in serum creatinine: Creatinine typically rises by 0.5-1.0 mg/dL per day in ATN, though rates can exceed 2-3 mg/dL/day in severe cases (especially rhabdomyolysis-associated). The rise is rapid enough that over 2-3 days, patients often progress from normal renal function to frank uremia.

• Hyperkalemia and metabolic acidosis: Both are direct consequences of loss of tubular secretory function and accumulation of hydrogen ions and potassium. Hyperkalemia may cause characteristic peaked T-waves on ECG, PR prolongation, and QRS widening. In severe cases, peaked T-waves may progress to loss of P-waves, sine-wave pattern, and cardiac standstill if potassium exceeds 7 mEq/L rapidly. Metabolic acidosis reflects inability to excrete hydrogen ions and retention of organic acids (uremic acidosis).

• Uremia and its complications: As GFR falls and urea/creatinine accumulate (often within 24-48 hours of onset), patients may develop altered mental status, confusion, or delirium. Pericarditis ("uremic pericarditis") can develop acutely in severe uremia and presents with chest pain, friction rub, and elevated troponin. Pulmonary edema from volume overload and increased capillary permeability; uremic edema is characteristically central (pulmonary) rather than peripheral. Uremic bleeding occurs due to platelet dysfunction (uremic toxins impair platelet aggregation) and may present as GI bleeding, epistaxis, or intracranial hemorrhage.

• Fluid overload: Oliguric ATN impairs sodium and water excretion, leading to hypertension, peripheral edema, pulmonary edema with dyspnea and orthopnea, and elevated jugular venous pressure (JVP). Weight gain (despite reduced oral intake) is a key clinical sign. In the ICU, this manifests as inability to wean from mechanical ventilation due to pulmonary edema.

• Anemia: Develops acutely due to decreased erythropoietin production, uremic hemolysis, GI blood loss, and blood loss from dialysis catheter placement or sampling. Hemoglobin may drop by 1-2 g/dL in the first 1-2 weeks.

• Hyperphosphatemia and hypocalcemia: Loss of phosphate excretion and impaired conversion of 25-OH vitamin D to active 1,25-dihydroxyvitamin D cause secondary hyperparathyroidism. Metastatic calcification can occur in severe cases, particularly in soft tissues.

• Gastrointestinal symptoms: Nausea, vomiting, anorexia, and abdominal discomfort are common uremic symptoms. Uremic frost (crystallized urea on skin) and uremic fetor (urine-like breath odor) indicate severe uremia with inadequate dialysis.

Laboratory findings specific to ATN pathophysiology

• Urinalysis with muddy brown casts: Pathognomonic for ATN. These casts consist of cellular debris, myoglobin (in rhabdomyolysis), or hemoglobin (in massive hemolysis). Granular casts (consisting of cellular debris) are also typical. The presence of epithelial cells, coarse granular casts, and the absence of red blood cell casts (which suggest glomerulonephritis) and white blood cell casts (which suggest interstitial nephritis) help distinguish ATN from other intrinsic kidney diseases. Proteinuria is mild to moderate (typically <1-2 g/day), in contrast to nephrotic-range proteinuria in glomerulonephritis or diabetic nephropathy.

• **Fractional excretion of

Step 1 — establish and stage the AKI

• Serum creatinine and urine output: The KDIGO 2012 AKI guideline defines AKI as a creatinine rise ≥0.3 mg/dL within 48 hours, a rise to ≥1.5× baseline within 7 days, or urine output <0.5 mL/kg/h for ≥6 hours. Stage 3 is creatinine ≥3× baseline, creatinine ≥4.0 mg/dL, anuria ≥12 hours, or initiation of renal replacement therapy.
• Renal ultrasound: Obtained early to exclude post-renal obstruction (hydronephrosis) and to assess for small echogenic kidneys indicating pre-existing CKD. Normal-sized, non-obstructed kidneys with a rising creatinine point toward intrinsic disease.

Step 2 — localize the lesion with urine microscopy (the single most informative test)

• Muddy brown granular casts and renal tubular epithelial cell casts: the classic sediment of ATN. Dysmorphic RBCs/RBC casts indicate glomerulonephritis; WBC casts with sterile pyuria suggest acute interstitial nephritis; a bland sediment favors prerenal azotemia or obstruction.
• Dipstick heme-positive urine with few RBCs on microscopy: pigment nephropathy — send CK (rhabdomyolysis) or hemolysis labs.

Step 3 — urine indices to separate ATN from prerenal azotemia

• FENa: >2% in ATN (tubules cannot reabsorb sodium) versus <1% in prerenal disease. FENa is invalid on loop diuretics — use FEUrea, where <35% suggests prerenal and >50% suggests ATN.
• Urine sodium >40 mEq/L and urine osmolality near isosthenuric (~300 mOsm/kg, generally <350) reflect lost concentrating ability.
• BUN:creatinine ratio <20:1 in ATN versus >20:1 prerenal.
• Caveat: FENa may be <1% early in ATN and in contrast-associated, pigment-induced, and sepsis-associated ATN — a low FENa does not exclude the diagnosis.

Confirmatory testing

• Renal biopsy is the histologic gold standard (tubular epithelial simplification, loss of brush border, cast-filled lumina) but is reserved for cases where the cause is unclear, another intrinsic disease such as rapidly progressive glomerulonephritis is suspected, or recovery fails to occur as expected.

Immediate stabilization

• Screen for emergent dialysis indications first (AEIOU: refractory Acidosis, Electrolyte derangement, Ingestion, fluid Overload, Uremic pericarditis/encephalopathy).
• Hyperkalemia with ECG changes: IV calcium gluconate to stabilize the myocardium, then insulin with dextrose ± inhaled beta-2 agonist to shift potassium intracellularly, then definitive removal with a potassium binder or dialysis.

First-line therapy

• Restore renal perfusion: isotonic crystalloid (balanced solution or normal saline) in the hypovolemic patient; the KDIGO guideline favors isotonic crystalloid over colloid for volume expansion. Vasopressors with fluids in vasodilatory shock — norepinephrine is the first-line agent per the Surviving Sepsis Campaign — targeting a mean arterial pressure adequate for renal autoregulation.
• Remove the insult: stop aminoglycosides, NSAIDs, ACE inhibitors/ARBs, and iodinated contrast; renally dose-adjust all remaining drugs; hold metformin.
• Rhabdomyolysis: early, aggressive isotonic fluid resuscitation targeting brisk urine output is the mainstay; urinary alkalinization is optional and not firmly evidence-based.

Escalation

• Renal replacement therapy for the emergent indications above. Randomized trials (AKIKI, STARRT-AKI) found no survival benefit to routine early initiation in the absence of a hard indication, and KDIGO supports an indication-driven approach.
• Nutrition and acidosis control: adequate protein/caloric intake; sodium bicarbonate for severe acidemia.

Explicitly contraindicated or not recommended

• Low-dose "renal-dose" dopamine: KDIGO recommends against it — no renoprotection and it increases arrhythmia and ischemic events.
• Loop diuretics to "convert" oliguric to non-oliguric ATN: not recommended; diuretics manage volume overload only and do not improve recovery or mortality.
• Mannitol, fenoldopam, and natriuretic peptides: not supported.
• N-acetylcysteine or bicarbonate for contrast prophylaxis: no benefit; the ACR–NKF consensus statement supports IV isotonic saline in high-risk patients (notably eGFR <30).

Emergencies

• Hyperkalemia: loss of distal tubular potassium secretion plus acidosis-driven transcellular shift. Signaled by peaked T waves, PR prolongation, QRS widening, then a sine-wave pattern preceding asystole. Treat before waiting for a repeat potassium.
• Pulmonary edema/volume overload: oliguric sodium and water retention; signaled by hypoxemia, orthopnea, elevated JVP, and failure to wean from the ventilator. Diuretic-refractory overload is a dialysis indication.
• Uremic pericarditis: uremic toxins inflame the pericardium; a pericardial friction rub with pleuritic chest pain. Risk of hemorrhagic effusion and tamponade — an absolute indication for urgent dialysis, and anticoagulation should be minimized.
• Uremic encephalopathy and seizures: asterixis, confusion, myoclonus; also a dialysis indication.

Non-emergent but expected

• Uremic platelet dysfunction: toxin-mediated impairment of platelet–vWF interaction with a normal platelet count and prolonged bleeding time; manifests as GI bleeding or oozing at line sites. Managed with desmopressin, cryoprecipitate, and dialysis.
• Metabolic acidosis with anion gap: retained organic acids and impaired ammoniagenesis.
• Hyperphosphatemia with hypocalcemia: reduced phosphate excretion and impaired 1-alpha-hydroxylation; in rhabdomyolysis, calcium sequesters in injured muscle and then rebounds to hypercalcemia during recovery.
• Infection: the leading cause of death in severe ATN — uremia impairs neutrophil and lymphocyte function, and dialysis catheters add a portal of entry.
• Polyuric recovery phase: as tubules regenerate, GFR returns before concentrating and reabsorptive capacity does, producing massive diuresis with hypovolemia, hypokalemia, and hypomagnesemia. Failure to replace losses causes a second ischemic hit.
• Progression to CKD or dialysis dependence: incomplete repair leaves interstitial fibrosis; AKI survivors need post-discharge creatinine and albuminuria follow-up, as emphasized by KDIGO.

Treatment-related

• Dialysis complications: intradialytic hypotension (further renal ischemia), catheter-related bloodstream infection, and dialysis disequilibrium syndrome from rapid urea clearance causing cerebral edema.
• Drug-specific: amphotericin B causes distal RTA with hypokalemia; aminoglycosides and cisplatin cause renal magnesium wasting.

• The buzzword pair: muddy brown granular casts plus FENa >2% equals ATN. RBC casts mean glomerulonephritis; WBC casts with eosinophiluria and a drug rash mean acute interstitial nephritis; a bland sediment with FENa <1% means prerenal azotemia.
• Single best next step in undifferentiated AKI: urinalysis with microscopy of the sediment, plus a renal ultrasound to exclude obstruction. Do not order a biopsy on a stem that already gives you muddy brown casts.
• The classic distractor: giving furosemide or "renal-dose" dopamine to increase urine output. Neither improves recovery or survival, and KDIGO recommends against low-dose dopamine. Diuretics treat volume overload only.
• FENa is unreliable on diuretics — switch to FEUrea. Also remember FENa can be <1% in contrast-associated ATN, pigment nephropathy, and early sepsis-associated ATN, so a low FENa does not exclude ATN.
• The timing association examiners love: contrast-associated AKI peaks around 3–5 days after exposure and usually recovers, whereas cholesterol embolization after arterial catheterization presents later with livedo reticularis, blue toes, eosinophilia, and low complement — a favorite mimic.
• Aminoglycoside ATN is classically non-oliguric and appears after roughly a week of therapy, often with hypomagnesemia and hypokalemia; amphotericin B produces distal RTA; cisplatin produces renal magnesium wasting.
• Heme-positive dipstick with no RBCs on microscopy = myoglobinuria or hemoglobinuria. Next step is CK; treatment is aggressive isotonic IV fluids, not a diuretic.
• Know the dialysis triggers cold (AEIOU): refractory acidosis, refractory hyperkalemia, toxic ingestion, refractory volume overload, and uremic pericarditis or encephalopathy. A friction rub in an azotemic patient means dialysis now — not NSAIDs, which are nephrotoxic.
• Anticipate the polyuric recovery phase: brisk diuresis with hypokalemia and hypovolemia signals healing tubules, not resolution of danger.